AM-Pharma presents positive Phase II results for potential First-In-Class drug
Alkaline Phosphatase improved renal function, reduced length of stay in Intensive Care, and could become First-in-Class drug in multi-billion market
15-Mar-2010 -
AM-Pharma B.V. announced positive results from its Phase II Acute Kidney Injury trial with Alkaline Phosphatase. The study showed that treatment of Acute Kidney Injury (AKI) with Alkaline Phosphatase results in improved renal function and reduced length of stay in Intensive Care. No drug ...
acute kidney injury
Belgium
dialysis
+3